Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

This week, Johnson & Johnson etched its name in the history books of another big pharma company that has been fined over billions of dollars due to a drug manufacturer practices of improper marketing and failure to warn.  Johnson & Johnson pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed [...]

November 7th, 2013|Actos Diabetes Drug, Avandia Diabetes Drug, DePuy Hip Replacement, Drug and Medical Device Litigation, Fosamax Osteoporosis Drug, Lipitor, Transvaginal Mesh|Comments Off on Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

New Jersey Fosamax Femur Fracture Trial Update

Glynn v. Merck Sharp & Dohme Corp. (3:11-cv-05304, U.S. District Court, District of New Jersey) started trial in April 2013.  Evidence was presented from internal documents and experts from both sides as to the benefits and risks of Fosamax.  The jury was asked to decide if Fosamax was defective, whether Merck provided adequate warnings, and [...]

April 30th, 2013|Drug and Medical Device Litigation, Fosamax Osteoporosis Drug|Comments Off on New Jersey Fosamax Femur Fracture Trial Update